Maze Therapeutics, Inc. (MAZE)

NASDAQ: MAZE · Real-Time Price · USD

12.39

-0.92 (-6.91%)

At close: Jun 17, 2025, 4:00 PM

13.33

+0.94 (7.59%)

Pre-market: Jun 18, 2025, 4:05 AM EDT

Maze Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	167.5	167.5	-	-
Gross Profit	167.5	167.5	-	-
Selling, General & Admin	28.1	26.42	24.61	22.83
Research & Development	89.2	83.5	73.95	88.19
Operating Expenses	117.3	109.91	98.55	111.03
Operating Income	50.2	57.59	-98.55	-111.03
Interest & Investment Income	6.99	4.65	1.97	2.03
Earnings From Equity Investments	-	-	-	-3.54
EBT Excluding Unusual Items	57.19	62.24	-96.59	-112.54
Gain (Loss) on Sale of Investments	-	-	-	-2.4
Other Unusual Items	-4.08	-8.84	-3.83	-
Pretax Income	53.11	53.4	-100.42	-114.94
Income Tax Expense	1.17	1.17	-	-
Net Income	51.94	52.23	-100.42	-114.94
Preferred Dividends & Other Adjustments	48.83	48.83	-	-
Net Income to Common	3.11	3.41	-100.42	-114.94
Shares Outstanding (Basic)	9	2	2	2
Shares Outstanding (Diluted)	9	3	2	2
Shares Change (YoY)	303.36%	19.33%	13.82%	-
EPS (Basic)	0.35	1.42	-43.89	-57.18
EPS (Diluted)	0.34	1.25	-43.89	-57.18
Free Cash Flow	68.71	74.81	-87.27	-101.17
Free Cash Flow Per Share	7.38	27.40	-38.14	-50.33
Gross Margin	100.00%	100.00%	-	-
Operating Margin	29.97%	34.38%	-	-
Profit Margin	1.86%	2.03%	-	-
Free Cash Flow Margin	41.02%	44.66%	-	-
EBITDA	53.23	60.88	-94.46	-107.21
EBITDA Margin	31.78%	36.35%	-	-
D&A For EBITDA	3.03	3.3	4.09	3.82
EBIT	50.2	57.59	-98.55	-111.03
EBIT Margin	29.97%	34.38%	-	-
Effective Tax Rate	2.21%	2.20%	-	-

Updated Mar 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q